[ad_1]
October 05, 2018
Belviq, a serotonin 2C receptor agonist, is approved for chronic weight management.
According to new data from the CAMELLIA-TIMI 61 study, treatment with lorcaserine (Belviq; Eisai) was associated with a reduced risk of incident diabetes in patients with prediabetes. The findings of the study were presented at the annual meeting of the European Association for Diabetes Research and published in The lancet.
Lorcaserin, a 2C serotonin receptor agonist, is currently approved as an adjunct to a low-calorie diet and increased physical activity for chronic weight management in adults with a Initial BMI ≥ 30 kg / m2 or ≥27 kg / m2 in the presence of at least one weight-related comorbidity (eg, hypertension, dyslipidemia, type 2 diabetes). In CAMELLIA-TIMI 61, researchers recruited overweight or obese patients at high risk of atherosclerotic vascular disease (N = 12,000) and randomized them to receive either lorcaserine or placebo. In this new analysis, researchers examined the long-term effects of the drug on diabetes prevention and remission in these patients. At baseline, 56.8% of patients were diabetic, 33.3% had prediabetes and 9.9% were normoglycemic. patients were followed for a median of 3.3 years.
The results showed that, compared to placebo, treatment with lorcaserine reduced the risk of incident diabetes by 19% (8.5% vs. 10.3%, HR 0.81, 95% CI: 0.66 to 0). , 99; P= 0.038) in patients with prediabetes and 23% in non-diabetic patients (6.7% vs. 8.4% HR 0.77, 95% CI 0.63 to 0.94; P= 0.012). In addition, lorcaserine was associated with a nonsignificant increase in the rate of achievement of normoglycemia in prediabetes patients (9.2% vs. 7.6%, HR 1.20, 0.97-1.49; P= 0.093) and increased the remission rate of hyperglycemia in diabetic patients (7.1% vs. 6.0%; HR 1.21, 1.00-1.45; P= 0.049).
In patients with diabetes, lorcarserin reduced HbA1c by 0.33% (95% CI: 0.29 to 0.38; P<.0001) from a mean baseline of 7.0%, compared with placebo at 1 year. In patients with baseline HbA1c >At 8.0%, lorcaserine was associated with an average reduction in HbA1c after 0.87% over one year (95% CI: 0.76-0.97), compared with 0.35% (95% CI: 0.23-0.46) for the placebo. In addition, treatment with lorcaserine reduced by 21% the risk of microvascular events (compound of incident microalbuminuria, diabetic retinopathy or neuropathy).
"The prevalence of diabetes is increasing, which is likely related in part to the growing prevalence of obesity," said Erin Bohula, MD, DPHIL cardiologist and investigator of the TIMI study group's staff, Brigham and Women's Hospital. "These data provide valuable information to physicians who treat overweight and obese patients with T2DM or who are at risk of developing T2D."
For more information, visit thelancet.com.
Scroll to see the next article
[ad_2]
Source link
